Stevenage, United Kingdom

Angus Harry Forster

This inventor holds 1 USPTO granted patent. Top assignee: Glaxo Group Limited. Active years: 2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Angus Harry Forster. Retrieved from https://idiyas.com/inventor/angus-harry-forster

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2012

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Angus Harry Forster: Innovator in Pharmaceutical Processing

Introduction: Angus Harry Forster is a prominent inventor based in Stevenage, GB, known for his significant contributions to the pharmaceutical industry. With a focus on improving drug formulations, Forster has developed a unique patent that addresses challenges in drug solubility.

Latest Patents: Angus Harry Forster holds one patent titled "Process for milling poorly soluble drugs in presence of liquid propellants." This innovative process involves co-milling a suspension of drug substances with a pharmaceutically acceptable polymer in a liquid propellant, facilitating the preparation of more effective pharmaceutical formulations.

Career Highlights: Forster currently works with Glaxo Group Limited, a major player in the pharmaceutical sector. His work at Glaxo allows him to apply his expertise in drug formulation and milling technologies, contributing to advancements in the industry.

Collaborations: Throughout his career, Forster has collaborated with notable colleagues, including James Matthew Butler and James Edon Patterson. These partnerships reflect a commitment to innovation and collaboration within the field of pharmaceuticals.

Conclusion: Angus Harry Forster’s work stands as a testament to the power of innovation in the pharmaceutical industry. His patent for milling poorly soluble drugs represents a significant step forward in drug formulation, promising to enhance the efficacy of medications and improve patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…